Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 12/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 5/20 | 0.38 |
| ▸ | CTSL | P07711 | 2/20 | 0.36 |
| ▸ | CTSB | P07858 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2846888 | 0.87 | CA1 (0.50) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL27277997 | 0.86 | CA1 (0.44) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL12487277 | 0.86 | CA1 (0.44) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL29130861 | 0.86 | CA1 (0.44) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL15071346 | 0.86 | CA1 (0.44) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL29255369 | 0.86 | CA1 (0.44) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL7834317 | 0.84 | CYP2D6 (0.55) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL168389 | 0.84 | CYP2D6 (0.55) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL3689498 | 0.84 | CYP2D6 (0.55) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL18428106 | 0.84 | CYP2D6 (0.55) | CYP2D6CA1CA2CA7CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122010782-A | Gelagliptin intermediate Process for the preparation of bulk compounds | 四川定科制药有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-8741927-B2 | Production method of intermediate compound for synthesizing medicament | LG LIFE SCIENCES LTD. (KR) | 2014-06-03 | — | — | US | disclosed |
| US-20130165659-A1 | PRODUCTION METHOD OF INTERMEDIATE COMPOUND FOR SYNTHESIZING MEDICAMENT | LG LIFE SCIENCES LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165659-A1 | PRODUCTION METHOD OF INTERMEDIATE COMPOUND FOR SYNTHESIZING MEDICAMENT | DPP4, DPP7, DPP8 | CYP2D6 147/4885CA1 1155/4885CA2 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.